Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
← catalyst calendarNCT06941870 · readout in 432 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
35estimated
Sites
13
Countries
Canada, Japan, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-23 | actual | When the study began enrolling |
| Primary completion | 2027-10-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-25 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Factor VIII Deficiency
Intervention
- Drug: Efanesoctocog alfa — also filed as BIVV001, ALTUVIIIO®
Primary outcome
what the primary-completion date above is the date OFProportion of joints with improvement in the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovitis domain score
measured From Baseline up to Week 52
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed